Doyle Mittie sold $11K of AVTX
Doyle Mittie (Chief Medical Officer) sold 679 shares of Avalo Therapeutics, Inc. (AVTX) at $16.00 on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The market may briefly note insider selling, but the explicit 10b5-1 plan and small transaction size make it unlikely to drive a sustained repricing by itself.
Market read
A routine 10b5-1 insider sale; treat as low-signal unless paired with additional negative company news.
What to watch
The filing does not indicate whether other insiders or large holders changed positions around the same time; without that context, price impact is likely muted.
Background
This is an SEC Form 4 insider transaction disclosure for Avalo Therapeutics, reported by its Chief Medical Officer.
Ticker impact
Avalo Therapeutics CMO Doyle Mittie sold 679 shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-01.
Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.
Form 4 shows a small dollar-value sale (~$10.9k) and explicitly notes a pre-arranged 10b5-1 plan, which typically dampens market sensitivity versus discretionary selling.
Market effects
Minimal; this is company-specific insider transaction with no stated operational/regulatory/drug-trial catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale was under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.
Key entities
- issuerAvalo Therapeutics, Inc.
Subject of the SEC Form 4 insider sale by its Chief Medical Officer.
- insiderDoyle Mittie
Chief Medical Officer who sold 679 shares at $16.00/share.
